Device Transactions Financing by device companies in the third quarter of 2017 totaled $2.38 billion, double Q2's $1.2 billion. ( See Exhibit 1. ) Debt again this quarter made up most of the aggregate
IN VITRO DIAGNOSTICS Financings Cancer Genetics Inc. Molecular diagnostics firm Cancer Genetics Inc. entered a financing agreement with Aspire Capital, through which Aspire will purchase, over the